» Articles » PMID: 38891812

Characterization of Humanized Mouse Model of Organophosphate Poisoning and Detection of Countermeasures Via MALDI-MSI

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Jun 19
PMID 38891812
Authors
Affiliations
Soon will be listed here.
Abstract

Organophosphoate (OP) chemicals are known to inhibit the enzyme acetylcholinesterase (AChE). Studying OP poisoning is difficult because common small animal research models have serum carboxylesterase, which contributes to animals' resistance to OP poisoning. Historically, guinea pigs have been used for this research; however, a novel genetically modified mouse strain (KIKO) was developed with nonfunctional serum carboxylase (Es1 KO) and an altered acetylcholinesterase (AChE) gene, which expresses the amino acid sequence of the human form of the same protein (AChE KI). KIKO mice were injected with 1xLD of an OP nerve agent or vehicle control with or without atropine. After one to three minutes, animals were injected with 35 mg/kg of the currently fielded Reactivator countermeasure for OP poisoning. Postmortem brains were imaged on a Bruker RapifleX ToF/ToF instrument. Data confirmed the presence of increased acetylcholine in OP-exposed animals, regardless of treatment or atropine status. More interestingly, we detected a small amount of Reactivator within the brain of both exposed and unexposed animals; it is currently debated if reactivators can cross the blood-brain barrier. Further, we were able to simultaneously image acetylcholine, the primary affected neurotransmitter, as well as determine the location of both Reactivator and acetylcholine in the brain. This study, which utilized sensitive MALDI-MSI methods, characterized KIKO mice as a functional model for OP countermeasure development.

Citing Articles

Neurological manifestations of encephalitic alphaviruses, traumatic brain injuries, and organophosphorus nerve agent exposure.

VanderGiessen M, de Jager C, Leighton J, Xie H, Theus M, Johnson E Front Neurosci. 2024; 18:1514940.

PMID: 39734493 PMC: 11671522. DOI: 10.3389/fnins.2024.1514940.

References
1.
Barry J, Groseclose M, Castellino S . Quantification and assessment of detection capability in imaging mass spectrometry using a revised mimetic tissue model. Bioanalysis. 2019; 11(11):1099-1116. DOI: 10.4155/bio-2019-0035. View

2.
Wong C, Cheng K, Papayannis I, Mattheolabakis G, Huang L, Xie G . Phospho-NSAIDs have enhanced efficacy in mice lacking plasma carboxylesterase: implications for their clinical pharmacology. Pharm Res. 2014; 32(5):1663-75. PMC: 4382427. DOI: 10.1007/s11095-014-1565-2. View

3.
Groseclose M, Castellino S . A mimetic tissue model for the quantification of drug distributions by MALDI imaging mass spectrometry. Anal Chem. 2013; 85(21):10099-106. DOI: 10.1021/ac400892z. View

4.
Jiang L, Chughtai K, Purvine S, Bhujwalla Z, Raman V, Pasa-Tolic L . MALDI-Mass Spectrometric Imaging Revealing Hypoxia-Driven Lipids and Proteins in a Breast Tumor Model. Anal Chem. 2015; 87(12):5947-5956. PMC: 4820759. DOI: 10.1021/ac504503x. View

5.
Aichler M, Walch A . MALDI Imaging mass spectrometry: current frontiers and perspectives in pathology research and practice. Lab Invest. 2015; 95(4):422-31. DOI: 10.1038/labinvest.2014.156. View